(macular degeneration[mesh] OR choroidal neovascularization[mesh] OR antineoplastic combined chemotherapy protocols[mesh] OR choroid[mesh] OR cyclophosphamide[mesh] OR heterocyclic compounds, 1-ring[mesh] OR macula lutea[mesh] OR mitoxantrone[mesh] OR retina[mesh] OR retinal diseases[mesh] OR vincristine[mesh] OR neovascularization, physiologic[mesh] OR heterocyclic compounds[mesh] OR contingent negative variation[mesh] OR maculopath*[Text Word] OR (neovasc*[Text Word] AND (macul*[Text Word] OR retina*[Text Word] OR choroid*[Text Word])) OR (macula*[Text Word] AND lutea[Text Word]) OR (AMD[Text Word] OR ARMD[Text Word] OR CNV[Text Word]) OR (degener*[Text Word] AND (macul*[Text Word] OR retina*[Text Word] OR choroid*[Text Word]))) AND (ranibizumab[mesh] OR recombinant fusion proteins[mesh] OR bevacizumab[mesh] OR receptors, vascular endothelial growth factor[mesh] OR aptamers, nucleotide[mesh] OR aspirin[mesh] OR drug combinations[mesh] OR growth[mesh] OR succinic acid[mesh] OR vascular endothelial growth factors[mesh] OR vascular endothelial growth factor a[mesh] OR endothelial cells[mesh] OR VEGF TRAP*[Text Word] OR (anti[Text Word] AND angiogen*[Text Word]) OR (macugen*[Text Word] OR pegaptanib*[Text Word] OR lucentis*[Text Word] OR rhufab*[Text Word] OR ranibizumab*[Text Word] OR bevacizumab*[Text Word] OR avastin[Text Word] OR aflibercept*[Text Word] OR conbercept*[Text Word]) OR (anti[Text Word] AND VEGF*[Text Word]) OR (endothelial[Text Word] AND growth[Text Word] AND factor*[Text Word]))